Pharma Capital

'Customer data validates strategy' for cancer diagnostic, says ANGLE PLC boss Andrew Newland

Andrew Newland, founder of ANGLE PLC (LON:AGL, OTCQX:ANPCY) runs Proactive through research carried out by the University of Athens and Attikon University Hospital which has found that their Parsortix system out-performs existing technology and, for the first time, is able to harvest head and neck cancer cells from patient blood for analysis.

 

View full AGL profile

ANGLE plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.